Estimated read time: 4-5 minutes
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
[STK]
[IN] HEA MTC MEQ
[SU] PER
TO HEALTH, NATIONAL, AND TECHNOLOGY EDITORS:
Covidien Chairman, President and CEO José Almeida Named Chairman of
AdvaMed's Board of Directors
WASHINGTON, March 26, 2014 /PRNewswire-USNewswire/ -- The Advanced
Medical Technology Association (AdvaMed) today announced that José
"Joe" E. Almeida, Chairman, President and CEO of Covidien, has been
named chairman of the AdvaMed Board of Directors for a two-year term.
Almeida has been an active member of the AdvaMed Board since 2005 and
its Executive Committee since 2010. He served as a former chair and
vice chair of the association's International Board Committee and
immediate past chair of its Ethics Committee. Almeida also was chair
of the AdvaMed 2012 Conference and Exhibition Committee, overseeing
the association's most successful and well-attended annual meeting to
date.
"It is a great honor to be chosen to lead and represent an
organization that distinguishes itself by promoting life-changing
innovations for patients worldwide," said Almeida. "Advances in
medical technology are allowing patients to live better, longer lives.
Yet the challenges of getting medical devices and diagnostics into the
hands of patients and physicians are still formidable, highlighting
the imperative for AdvaMed and continued industry partnership."
As chairman, Almeida will focus on strategic initiatives to ensure the
United States maintains its global competitiveness in medical
innovation and that patients worldwide have access to the latest med
tech advances. Among his priorities, Almeida will:
-- Work with the U.S. Food and Drug Administration to ensure progress
on improving the timeliness of medical technology reviews, in line
with the agency's commitments under the latest user fee deal;
-- Advance pro-innovation and pro-competition tax policies, and
support repeal of the medical device excise tax;
-- Pursue global regulatory harmonization initiatives to help reduce
unnecessary and redundant regulations, which limit patient access and
drive health care costs; and,
-- Promote AdvaMed's Code of Ethics globally, with particular emphasis
on adoption of common codes of ethics in Asia and Latin America.
"AdvaMed is delighted and extremely fortunate to have Joe as its new
chairman," said AdvaMed President and CEO Stephen J. Ubl. "He is a
dynamic leader who brings a wealth of knowledge and global perspective
on issues impacting our industry as well as an unwavering commitment
to medical innovation and improvement in patient care."
Almeida succeeds Zimmer President and CEO David C. Dvorak, who has led
the Board since 2012.
"David's chairmanship has been extraordinarily impactful and
successful," Ubl said. "We are grateful for his tireless dedication to
the association, to the industry and, most of all, to the patients
worldwide we all serve."
Among AdvaMed's accomplishments under Dvorak's leadership were:
-- Continued proactive and constructive engagement with FDA on a range
of important issues, including implementation of the agency's
reauthorized user fee program, a final unique device identification
regulation, and new post-market surveillance initiatives;
-- Sharpened focus on the impact of the medical device tax and
significant progress in the industry's efforts to repeal the tax; and,
-- The launch and implementation of AdvaMed's strategic plan, which
aims to increase the association's presence and advocacy work in key
emerging markets, bolster its research capacity and strengthen member
engagement activities.
AdvaMed also announced new committee and Board chairs for 2014-2016:
-- Nominating Committee - David. C. Dvorak, President and CEO, Zimmer
Holdings
-- Treasurer & Finance, Audit & Compensation Committee - Kieran T.
Gallahue, Chairman and CEO, CareFusion
-- Secretary - Jeffrey R. Binder, CEO, Biomet
-- Payment & Healthcare Delivery - Timothy M. Ring, Chairman and CEO,
C. R. Bard
-- Technology & Regulation - Vincent A. Forlenza, Chairman, President
and CEO, BD
-- International - Debra A. Rectenwald, President and General Manager,
3M Infection Prevention Division Health Care Business
-- Membership - Peter J. Arduini, President and CEO, Integra
LifeSciences
-- Legal - Gerhard F. Burbach, President, CEO and Director, Thoratec
-- Ethics and Healthcare Compliance - Michael A. Mussallem, Chairman
and CEO, Edwards Lifesciences
-- AdvaMed PAC - Michael R. Minogue, Chairman, President and CEO,
Abiomed
-- Industry Communications - Caroll H. Neubauer, Chairman and CEO, B.
Braun Medical
-- Strategic Planning - Mike Genau, Senior Vice President and
President, U.S. Region, Medtronic
-- Emerging Growth Company Council - Nadim Yared, President and CEO,
CVRx
-- AdvaMedDx - John L. Bishop, Chairman and CEO, Cepheid
AdvaMed member companies produce the medical devices, diagnostic
products and health information systems that are transforming health
care through earlier disease detection, less invasive procedures and
more effective treatments. AdvaMed members range from the largest to
the smallest medical technology innovators and companies. For more
information, visit www.advamed.org .
SOURCE AdvaMed
-0- 03/26/2014
/CONTACT: Mark Brager, mbrager@advamed.org, (202) 434-7244
/Web Site: http://www.advamed.org
CO: AdvaMed
ST: District of Columbia
IN: HEA MTC MEQ
SU: PER
PRN
-- DC90579 --
0000 03/26/2014 13:00:00 EDT http://www.prnewswire.com
Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
